MiraDx

About

MiraDx is a molecular genetics company based in Los Angeles, co-founded in 2008 by Dr. Joanne Weidhaas and Dr. Frank Slack. The company is dedicated to advancing personalized medicine through the use of germline genetic biomarkers, particularly focusing on microRNA biology. This approach aims to optimize cancer treatment strategies and predict therapy-related toxicities. MiraDx operates a CLIA-certified laboratory and has shown adaptability by providing COVID-19 testing for essential workers during the pandemic. The company collaborates with academic and industry partners globally to enhance biomarker applications. Its offerings include KRAS-variant testing, which helps guide cancer treatment decisions, and in-development tests like PREVIOTOX and PROSTOX, designed to assess risks associated with immunotherapy and personalize radiation therapy recommendations, respectively. MiraDx primarily serves oncologists and cancer patients, with a commitment to improving treatment outcomes through innovative genetic insights.